Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTEMIS: ziltivekimab versus placebo in patients with acute myocardial infarction
CTR20243145Phase 3Active
- Sponsor
- Novo Nordisk
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of ziltivekimab in myocardial infarction (MI), sponsored by Novo Nordisk. Started Oct 2024; status: active.
02
Drugs
ziltivekimab
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on CTR20243145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243145.